“…In the literature, there are 10 cases of iTTP that, despite achieving clinical remission, could not achieve ADAMTS13 activity and received plasma cell-directed therapy. 7,38,39,53,54 In accordance with prior definitions of ADAMTS13 complete and partial remission, 31 among the seven patients treated with bortezomib, ADAMTS13 remission was achieved in five patients (one with partial remission, four with complete remission), while among the three patients treated with daratumumab, complete remission was obtained in two patients, and responses were not achieved in one patient. While the patient in the bortezomib group who achieved partial remission was accompanied by systemic lupus erythematosus, one of the two patients in the bortezomib group who did not achieve remission was accompanied by Crohn's disease, and an ADAMTS13 response was obtained after infliximab.…”